{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:07:44Z","timestamp":1791223664751,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9,24]]},"DOI":"10.1097\/qad.0b013e32833dec20","type":"journal-article","created":{"date-parts":[[2010,8,27]],"date-time":"2010-08-27T15:12:43Z","timestamp":1282921963000},"page":"2365-2374","source":"Crossref","is-referenced-by-count":147,"title":["Efficacy of darunavir\/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136"],"prefix":"10.1097","volume":"24","author":[{"given":"Christine","family":"Katlama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A","family":"Valantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Algarte-Genin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Duvivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidonie","family":"Lambert-Niclot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre M","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Hoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Pakianather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne G","family":"Marcelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Flandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1468-1293.2007.00533.x","article-title":"N, Pozniak A, Raffi F and EACS executive committee. European AIDS Clinical Society (EACS) Guidelines for the Clinical Management and Treatment of HIV infected adults.","volume":"9","year":"2008","journal-title":"HIV Med"},{"key":"R2-9-20210130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0140-6736(03)13802-0","article-title":"Decline in the AIDS and death rates in the EuroSIDA study: an observational study","volume":"362","author":"Mocroft","year":"2003","journal-title":"Lancet"},{"key":"R3-9-20210130","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1097\/00002030-199814000-00004","article-title":"Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway","volume":"12","author":"Brinkman","year":"1998","journal-title":"AIDS"},{"key":"R4-9-20210130","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e32832995fa","article-title":"HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial","volume":"23","author":"Calmy","year":"2009","journal-title":"AIDS"},{"key":"R5-9-20210130","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1097\/QAD.0b013e3283313c91","article-title":"HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy","volume":"23","author":"Choi","year":"2009","journal-title":"AIDS"},{"key":"R6-9-20210130","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","article-title":"Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension study","volume":"18","author":"Martin","year":"2004","journal-title":"AIDS"},{"key":"R7-9-20210130","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"key":"R8-9-20210130","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1086\/589622","article-title":"A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy","volume":"198","author":"Cameron","year":"2008","journal-title":"J Infect Dis"},{"key":"R9-9-20210130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/01.aids.0000161777.38438.ed","article-title":"Lopinavir\/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients","volume":"19","author":"Campo","year":"2005","journal-title":"AIDS"},{"key":"R10-9-20210130","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/135965350901400210","article-title":"Risk factors for loss of virological suppression in patients receiving lopinavir\/ritonavir monotherapy for maintenance of HIV suppression","volume":"14","author":"Pulido","year":"2009","journal-title":"Antivir Ther"},{"key":"R11-9-20210130","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1086\/597119","article-title":"Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes","volume":"199","author":"Wilkin","year":"2009","journal-title":"J Infect Dis"},{"key":"R12-9-20210130","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1086\/521933","article-title":"Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial","volume":"45","author":"Schackman","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R13-9-20210130","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/QAD.0b013e32832cbcec","article-title":"Characterization of virologic failure patients on darunavir\/ritonavir in treatment-experienced patients","volume":"23","author":"De Meyer","year":"2009","journal-title":"AIDS"},{"key":"R14-9-20210130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAD.0b013e328013d9d7","article-title":"Efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1","volume":"21","author":"Katlama","year":"2007","journal-title":"AIDS"},{"key":"R15-9-20210130","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/aid.2008.0216","article-title":"Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals","volume":"25","author":"Yilmaz","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R16-9-20210130","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1310\/hct0906-418","article-title":"Pharmacokinetics, efficacy, and safety of darunavir\/ritonavir 800\/100 mg once-daily in treatment-naive and -experienced patients","volume":"9","author":"Boffito","year":"2008","journal-title":"HIV Clin Trials"},{"key":"R17-9-20210130","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0b013e3282f4243b","article-title":"Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV","volume":"22","author":"Pulido","year":"2008","journal-title":"AIDS"},{"key":"R19-9-20210130","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1128\/AAC.49.6.2314-2321.2005","article-title":"TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates","volume":"49","author":"De Meyer","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-9-20210130","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1021\/jm049454n","article-title":"Design of HIV-1 protease inhibitors active on multidrug-resistant virus","volume":"48","author":"Surleraux","year":"2005","journal-title":"J Med Chem"},{"key":"R21-9-20210130","first-page":"138","article-title":"Update of the drug resistance mutations in HIV-1","volume":"16","author":"Johnson","year":"2008","journal-title":"Top HIV Med"},{"key":"R22-9-20210130","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00042560-200111010-00005","article-title":"The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort","volume":"28","author":"Carrieri","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R23-9-20210130","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jama.295.10.1152","article-title":"Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement","volume":"295","author":"Piaggio","year":"2006","journal-title":"JAMA"},{"key":"R24-9-20210130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/QAD.0b013e3283348944","article-title":"The MONET trial: darunavir\/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies\/ml","volume":"24","author":"Arribas","year":"2010","journal-title":"AIDS"},{"key":"R25-9-20210130","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa0906768","article-title":"Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy","volume":"361","author":"Sax","year":"2009","journal-title":"N Engl J Med"},{"key":"R26-9-20210130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QAD.0b013e3282f3f16d","article-title":"Lopinavir\/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients","volume":"22","author":"Delfraissy","year":"2008","journal-title":"AIDS"},{"key":"R27-9-20210130","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1128\/AAC.01643-08","article-title":"Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy","volume":"53","author":"Delaugerre","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-9-20210130","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N Engl J Med"},{"key":"R29-9-20210130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/135965350901400105","article-title":"Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK trial randomized to ritonavir-boosted lopinavir alone","volume":"14","author":"Flandre","year":"2009","journal-title":"Antivir Ther"},{"key":"R30-9-20210130","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1086\/650538","article-title":"Discordance between CSF and plasma HIV replication in patients with neurological symptoms and suppressive antiretroviral therapy.","volume":"50","author":"Canestri","year":"2010","journal-title":"Clin Infect Dis"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002030-201009240-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T04:45:29Z","timestamp":1740458729000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201009240-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,24]]},"references-count":29,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32833dec20","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9,24]]}}}